Have you been diagnosed with multiple myeloma or high-risk smoldering multiple myeloma? If so, you may be able to take part in a research study looking at how drugs used to treat multiple myeloma work.

Researchers are studying different doses of a therapy (CD19 CAR T-cells) to find the dose that is both the most effective and the safest for patients with relapsed or refractory B-cell lymphoma.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.

Have you been diagnosed with melanoma? If so, you may be eligible to take part in a research study looking at the safety of giving a combination of drugs called Ulixertinib and Palbociclib to patients with advanced melanoma.

The purpose of this study is to establish a safe dose of study cells (ALTCAR.CD30) to give after chemotherapy and estimate progression free survival in pediatric patients with CD30+ refractory/relapsed Hodgkin lymphoma (HL) and non-Hodgkin lymphoma.

Do you have bladder, kidney, prostate, or another genitourinary cancer diagnosis? If so, you may be able to take part in a research study collecting specimens (e.g., blood, urine, saliva, tissue) during your already scheduled appointments. Collecting these specimens may help researchers develop new ways to detect cancer earlier or to more effectively treat cancer.

Develop a set of effective little cigar and cigarillo warning statements.

The purpose of the study is to find the best dose for study drug FG-3246, based on safety and the ability of the study drug to shrink your tumor and delay progression of disease, in men with metastatic castration-resistant prostate cancer.

The main goal of this project is to create an interactive online version of the Let's Talk program and test it with patients who have Lynch syndrome to see if it works well in a medical setting.

We propose to develop and test health messages about e-cigarettes and study their impact. Findings will inform e-cigarette warning policies and communication campaigns.